Polaryx Therapeutics, Inc.
PLYX
Analytical Summary
Polaryx Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.
5-Year Financial Trajectory
QuarterlyBullish Indicators
- No bullish signals detected.
Bearish Risks
- Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|
| EPS Growth YoY (%) |
54.5%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — | — | — |
| Net Income Growth YoY (%) |
49.6%
Excellent
Excellent
Year-over-year change in net income |
— | — | — | — |
| FCF Growth YoY (%) |
-173.2%
Weak
Weak
Year-over-year change in free cash flow |
— | — | — | — |
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|
| FCF / Net Income (x) |
0.81x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
0.14x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
— | — |
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|
| Return on Invested Capital (%) |
-62.2%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
-93.8%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— | — |
| Return on Capital (%) (%) |
-55.9%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— | — | — | — |
| Return on Common Equity (%) (%) |
-102.3%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-782%)
|
— |
-118.8%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-892%)
|
— | — |
Secondary lens
Benchmark Lens
Compare PLYX against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare PLYX against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for PLYX
No bullish signals detected
Return on Common Equity (%) is in the bottom quartile
Percentile Rankings
How PLYX compares to all companies
Peer Comparison
PLYX vs similar peers
Compare PLYX with peers
Stack PLYX against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 3 years · 5 quarters